Novo Nordisk's decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly's own similar drug, industry sources said.
Mounjaro is expected to become available through the NHS for the treatment of type 2 diabetes later this year. On Friday Britain's drug cost-effectiveness watchdog NICENovo's type 2 diabetes drug Ozempic has been on the market in Britain since 2019.
In July, Britain's Department of Health and Social Care issued a medicine supply notification which did not name Ozempic but said there were "very limited, intermittent" supplies of the GLP-1 receptor agonist drugs approved to treat Type 2 diabetes. To increase production, Novo is spending billions on new plants and hiring additional contract manufacturers.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billionAs Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
Read more »
USD/CAD Price Analysis: Defends 1.3650 resistance-turned-support ahead of Canadian jobs dataThe USD/CAD pair comes under some selling pressure on Friday and reverses a part of the previous day's positive move to the 1.3700 neighbourhood, or i
Read more »
Analysis-Oil cut extension raises risk of Saudi economic contraction this year By ReutersAnalysis-Oil cut extension raises risk of Saudi economic contraction this year
Read more »
Analysis: Oil cut extension raises risk of Saudi economic contraction this yearSaudi Arabia faces the risk of an economic contraction this year following its decision to extend crude production cuts, highlighting its still heavy reliance on oil as reforms to diversify are slow moving.
Read more »
USD/CHF Price Analysis: Seems supported above 0.8900 due to resilient US DollarThe USD/CHF pair rebounds after correcting to near the crucial support of 0.8900, supported by the resilient US Dollar amid the risk-off market mood.
Read more »
Analysis-Potential US government shutdown could dent investor confidence By ReutersAnalysis-Potential US government shutdown could dent investor confidence
Read more »